Boston Scientific is dealing with a Class II recall of 9,750 Orca sterile, single-use air/water and suction valves after higher-than-expected reports of suction buttons sticking during gastrointestinal endoscopy procedures. The recall, initiated by the firm and posted by the FDA in June 2026, affects nationwide US distribution and adds to regulatory pressures on the diversified medical technology company. Meanwhile, Truist Securities cut its Boston Scientific price target from US$85 to US$64, citing softness in Watchman device demand, with management flagging flat Watchman revenue through the third quarter of 2026. These developments are shaping the investment narrative around Boston Scientific, as quality issues in ancillary devices compound concerns about near-term execution risks.
Boston Scientific CorpTruist cut price target citing soft Watchman demand; management flagged flat Watchman revenue through Q3 2026.